Should women 30-39 years old with focal breast symptoms undergo US, mammography or both?

Targeted breast ultrasound should be the initial imaging evaluation for women between the ages of 30 and 39 presenting with focal breast symptoms, according to a new study published in the American Journal of Roentgenology. Mammography can provide some value in detecting cancers distant from the area of clinical concern, yet its cancer detection rate (CDR) in such a scenario is still rather low.

Overnight attending radiologist coverage leads to reduced turnaround times, higher satisfaction among referring clinicians and increased educational value for residents, according to new research published in Current Problems in Diagnostic Radiology.

Age-adjusted lung cancer mortality in the United States is estimated to decrease by 79 percent between 2015 and 2065, according to a new study published in the Annals of Internal Medicine. However, the authors noted, millions of lung cancer deaths are still projected during that time, making it especially important to emphasize screening in the years ahead.

Researchers at the University of California, Los Angeles (UCLA) School of Medicine and School of Dentistry have been awarded a five-year, $5 million grant from the National Cancer Institute to develop liquid biopsy tools as a method for lung cancer screening.

The Medical Imaging & Technology Alliance (MITA) has issued a statement in support of the FDA’s recent efforts to strengthen its medical device cybersecurity program.

RaySearch Laboratories, a Stockholm-based medical technology company, and Canon Medical Systems Corporation have announced a new collaboration focused on integrating two of RaySearch’s software products—including RayStation and RayCare—into Canon Medical’s imaging and advanced visualization solutions.

In an effort to curb lung cancer mortality in the U.K., a National Health Service (NHS) pilot program will employ mobile CT scanning units in grocery store parking lots. The program will target more than 7,000 current and former smokers, aged 60 to 75, to detect tumors.

It was yet another entry in a familiar medical-news narrative: A big breakthrough in the treatment of Alzheimer’s disease gets called into question by subsequent reporting. Only this time the off notes hit while the fanfare was still sounding.